At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...

COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...

FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...

SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...

VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...

MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...

HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg ...

Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research / ...

Daraxonrasib Versus Chemotherapy in Metastatic Pancreatic Cancer – Additional Subgroup Analyses / cancer, cancer care, Cancer ...

Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...

Frontline Magrolimab Plus Azacitidine in Higher-Risk MDS / cancer, ENHANCE trial, Hematology, magrolimab, MDS, ...